Most in US suppose cannabis has health benefits, despite lack of data- analyze

Survey respondents believe drug can alleviate various ailments, even as scientists call out for more research

Americans believe marijuana is helpful in treating a variety of health problems despite a lack of available evidence supporting it, a new survey observed.

The results, to be published in the upcoming issue of the Annals of Internal Medicine, prove the most respondents believe smoking marijuana can help with pain management and then MS. Just under half believe it can alleviate insomnia, nervousnes and depression, ailments for which marijuana’s efficacy and safety have not been established by scientists.

” They believe things that we have no data for ,” said the study’s lead author, Dr Salomeh Keyhani, a professor of general internal medicine at the University of California San Francisco medical school.

Of the 16,000 respondents to the online survey, 14.6% said they had employed marijuana in the past year, lower than in the country at large, according to a 2017 survey.

In the US, marijuana’s unique legal situation complicates efforts to study and obtain accurate information about the drug’s harms and benefits.

According to the US Drug Enforcement Administration, the agency responsible for drug law enforcement, marijuana is a schedule I drug, meaning that it has serious hazards and no medical benefits. Other drugs in this category include heroin and LSD.

This restricted status makes it difficult for scientists to study marijuana, especially its health benefits.

” We need better data ,” Keyhani said.” We need any data .”

She attributes the gaps between public perception and proved science largely to commercialization of the narcotic in several US countries, which has led to advertising and media coverage.

Thirty-one US countries have decriminalize cannabis for medical use. Photograph: Gareth Fuller/ PA

To pro-cannabis activists, the lack of traditional research gives credibility to anecdotal evidence, or allows them to point to research on animals or from pre-clinical lab examines not normally used to demonstrated a substance’s medical benefits for humans.

At the same time, marijuana’s schedule I status “ve lost” credibility in recent years. In June, the US Food and Drug Administration( FDA) approved Epidiolex, a first for a drug derived from the marijuana plant. The narcotic, developed by the UK firm GW Pharmaceuticals, won approval to treat certain severe pediatric epilepsy disorders.

In addition, 31 US nations have legalized medical marijuana for a wide various forms of illnesses, such as post-traumatic stress ailment, for which there is not medical proof of efficacy. To alleviate the current opioids crisis some nations, including New York, are willing to allow anyone prescribed an opioid wide latitude to replace it with medical marijuanas.

The survey also procured 18% of US adults believe smoking marijuana is somewhat or completely safe for adults. A smaller segment of the population, 7.3% believe it is somewhat or completely safe for children to be exposed to secondhand pot smoke and that marijuana use is safe during pregnancy. These faiths do not have a basis in mainstream science.

The most common perils respondents associated with marijuanas use were legal problems, addiction and impaired memory.

A recent analyze in the Lancet determined marijuana does not reduce chronic ache or help replace opioids.

However, a different recent analyze published in the periodical Addiction procured an association between states which have decriminalize medical marijuana and a reduction in prescriptions for schedule III opioids. It did not find evidence of drops in prescriptions for more powerful schedule II opioids.

Mixed signals regarding marijuana’s potential dangers and benefits have enabled the commercial marijuana industry to promote a maximalist view of marijuana’s possible benefits. Since direct unproven claims of marijuana’s medical benefits, and affirms such as that a product cures cancer, can lead to unwanted attention from the FDA regulators, cannabis companies have learned to be much more subtle.

Starting with the largely uncontested assertion that no one has ever died from a marijuana overdose, companies will often go on to promote softer, if still unproven , notions of cannabis’s curative properties. For instance, the website of the California company Papa& Barkley features testimonies from customers who say the company’s products alleviated their arthritis ache, nervousnes, insomnia and a guitarist’s thumb cramps.

Read more:

Leave a Reply

Your email address will not be published. Required fields are marked *